粉砕して溶液に溶解したベネトクラクス錠の薬物動態研究
血液悪性腫瘍の小児および若年成人を対象に、ベネトクラクス錠を粉砕して溶液に溶解した薬物動態研究
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.
Primary Objectives
• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution
Secondary Objectives
- To evaluate the safety of crushed venetoclax tablets administered as an oral solution
- To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors
- To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)
- To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution
調査の概要
状態
条件
詳細な説明
Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Site Public Contact
- 電話番号:(513) 636-2799
- メール:cancer@cchmc.org
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- Children's Hospital Colorado
-
主任研究者:
- Kelly Faulk, MD
-
コンタクト:
- Kelly Faulk, MD
- 電話番号:720-777-5771
- メール:Kelly.Faulk@childrenscolorado.org
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- まだ募集していません
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital
-
コンタクト:
- Himalee Sabnis, MD, MS
- 電話番号:57922 404-785-3627
- メール:Himalee.sabnis@choa.org
-
主任研究者:
- Himalee Sabnis, MD, MS
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- 募集
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Children's Hospital of Philadelphia
-
主任研究者:
- Sarah Tasian, MD
-
コンタクト:
- Tasleema Patel
- 電話番号:917-818-6971
- メール:patelt6@chop.edu
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- Texas Children's Hospital
-
コンタクト:
- Michelle Redell, MD
- 電話番号:832-822-4242
- メール:mlredell@texaschildrens.org
-
コンタクト:
- Grace Anand
- 電話番号:832-824-7705
- メール:gxanand@texaschildrens.org
-
主任研究者:
- Michelle Redell, MD
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- 募集
- Children's Hospital of Wisconsin
-
主任研究者:
- Zachary Graff, MD
-
コンタクト:
- Kira Mielke
- メール:kmielke@mcw.edu
-
コンタクト:
- Kara Nelson
- メール:knelson@mcw.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
Patients must be <39 years of age at time of study enrollment.
説明
Inclusion Criteria:
- Age: Patients must be <39 years of age at time of study enrollment
- Diagnosis: Patients may have a diagnosis of any hematologic malignancy
- Central access: Patients must have an existing venous or arterial access line for PK blood draws
- Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
- Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
- Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.
Exclusion Criteria:
- Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
- Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:OTHER
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Children and Young Adults
Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care. |
Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
時間枠:Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
時間枠:Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the time to peak (Tmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
時間枠:Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the apparent terminal phase elimination rate constant (β) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
時間枠:Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the terminal-phase elimination half-life (T1/2) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
時間枠:Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
時間枠:Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: oral clearance (CL/F) of venetoclax |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
時間枠:Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
時間枠:Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the time to peak (Tmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
時間枠:Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the apparent terminal phase elimination rate constant (β) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
時間枠:Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the terminal-phase elimination half-life (T1/2) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
時間枠:Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
時間枠:Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: oral clearance (CL/F) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
協力者と研究者
捜査官
- 主任研究者:Lauren Pommert, MD、Children's Hospital Medical Center, Cincinnati
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 病理学的プロセス
- 部位別新生物
- 新生物
- 慢性疾患
- 疾患の属性
- 免疫系疾患
- 感染症
- ウイルス病
- 組織型別の新生物
- 血液疾患
- DNAウイルス感染症
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- 白血病、骨髄性
- 骨髄疾患
- 白血病、リンパ
- エプスタイン-バーウイルス感染症
- ヘルペスウイルス感染症
- 腫瘍ウイルス感染症
- 病理学的状態、徴候および症状
- ヘミックおよびリンパ疾患
- 白血病
- 白血病、骨髄性、急性
- 血液腫瘍
- リンパ腫
- リンパ腫、B細胞
- リンパ腫、大型B細胞、びまん性
- 前駆細胞リンパ芽球性白血病-リンパ腫
- バーキットリンパ腫
- リンパ腫、非ホジキン
- リンパ腫、濾胞性
- 骨髄増殖性疾患
- ホジキン病
- リンパ腫、T細胞
- リンパ腫、T細胞、末梢
- 白血病、骨髄性、慢性、BCR-ABL陽性
その他の研究ID番号
- Venetoclax PK
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。